
Redeye Initiates Coverage of Cinclus Pharma

Redeye initiates coverage of Cinclus Pharma, a Swedish biotech company offering a next-generation solution to the USD+5bn GERD treatment market. Building on its superior efficacy, a robust safety profile and being on the brink of pivotal studies, the lead candidate linaprazan glurate has a clear-cut pathway to the market. Bolstered by a strong management and a newly secured financial runway, we see a case with blockbuster potential.

[Read more and download the Research Report.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Redeye Initiates Coverage of Cinclus Pharma](#)